{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:47:13Z","timestamp":1790520433887,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2003,2,1]],"date-time":"2003-02-01T00:00:00Z","timestamp":1044057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2003,2]]},"DOI":"10.1067\/mai.2003.78","type":"journal-article","created":{"date-parts":[[2003,4,24]],"date-time":"2003-04-24T00:57:16Z","timestamp":1051145836000},"page":"S560-S570","source":"Crossref","is-referenced-by-count":55,"special_numbering":"S2","title":["11. Allergic and immunologic diseases of the skin"],"prefix":"10.1067","volume":"111","author":[{"given":"Andrew","family":"Blauvelt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam T.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Udey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1067\/mai.2003.78_bib1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0190-9622(85)70188-0","article-title":"Psoriasis of early and late onset: Characterization of two types of psoriasis vulgaris","volume":"133","author":"Henseler","year":"1985","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mai.2003.78_bib2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/archderm.1974.01630020023005","article-title":"Natural history of psoriasis in 61 twin pairs","volume":"109","author":"Farber","year":"1974","journal-title":"Arch Dermatol"},{"key":"10.1067\/mai.2003.78_bib3","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1001\/archderm.137.11.1447","article-title":"The genetics of psoriasis 2001: The odyssey continues","volume":"137","author":"Elder","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1067\/mai.2003.78_bib4","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1046\/j.1523-1747.1998.00390.x","article-title":"Autocrine regulation of ke-ratinocytes: The emerging role of heparin-binding, epidermal growth factor-related growth factors","volume":"111","author":"Piepkorn","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1067\/mai.2003.78_bib5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/jaut.1999.0343","article-title":"CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: Blood and skin comparisons by flow cytometry","volume":"14","author":"Ferenczi","year":"2000","journal-title":"J Autoimmun"},{"key":"10.1067\/mai.2003.78_bib6","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/1523-1747.ep12371679","article-title":"The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response","volume":"101","author":"Uyemura","year":"1993","journal-title":"J Invest Dermatol"},{"key":"10.1067\/mai.2003.78_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/1523-1747.ep12371752","article-title":"T cells involved in psoriasis vulgaris belong to the Th1 subset","volume":"102","author":"Schlaak","year":"1994","journal-title":"J Invest Dermatol"},{"key":"10.1067\/mai.2003.78_bib8","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1046\/j.1523-1747.1999.00749.x","volume":"113","author":"Austin","year":"1999","journal-title":"J Invest Dermatol"},{"key":"10.1067\/mai.2003.78_bib9","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1172\/JCI1476","article-title":"IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: A new therapeutic approach","volume":"101","author":"Asadullah","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1067\/mai.2003.78_bib10","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/labinvest.3780242","article-title":"Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris","volume":"81","author":"Rottman","year":"2001","journal-title":"Lab Invest"},{"key":"10.1067\/mai.2003.78_bib11","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1001\/jama.1986.03380220076026","article-title":"Cyclosporine improves psoriasis in a double-blind study","volume":"256","author":"Ellis","year":"1986","journal-title":"JAMA"},{"key":"10.1067\/mai.2003.78_bib12","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nm0595-442","article-title":"Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis","volume":"1","author":"Gottlieb","year":"1995","journal-title":"Nat Med"},{"key":"10.1067\/mai.2003.78_bib13","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1172\/JCI5857","article-title":"CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris","volume":"103","author":"Abrams","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1067\/mai.2003.78_bib14","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1067\/mjd.2000.106515","article-title":"Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis","volume":"43","author":"Krueger","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mai.2003.78_bib15","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1067\/mjd.2000.107945","article-title":"Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: Results of a pilot, multicenter, multiple-dose, placebo- controlled study","volume":"43","author":"Gottlieb","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mai.2003.78_bib16","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1056\/NEJM200107263450403","article-title":"Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes","volume":"345","author":"Ellis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1067\/mai.2003.78_bib17","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1067\/mai.2003.78_bib18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1067\/mai.2003.78_bib19","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1001\/archderm.138.10.1341","article-title":"Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10","volume":"138","author":"Kimball","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1067\/mai.2003.78_bib20","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1172\/JCI6910","article-title":"Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions","volume":"104","author":"Trepicchio","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1067\/mai.2003.78_bib21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1523-1747.2000.00abs-8.x","article-title":"Anti-CD11a treatment for psoriasis concurrently increases circulating T- cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking","volume":"11","author":"Krueger","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1067\/mai.2003.78_bib22","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/archderm.138.5.591","article-title":"Psoriasis as a model for T-cell-mediated disease: Immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody","volume":"138","author":"Gottlieb","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1067\/mai.2003.78_bib23","first-page":"862","year":"2001"},{"key":"10.1067\/mai.2003.78_bib24","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0952-7915(01)00287-4","article-title":"T-cell subpopulations in the development of atopic and contact allergy","volume":"13","author":"Girolomoni","year":"2002","journal-title":"Curr Opin Immunol"},{"key":"10.1067\/mai.2003.78_bib25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1615\/CritRevImmunol.v21.i5.30","article-title":"Induction and regulation of T-cell priming for contact sensitivity","volume":"21","author":"Gorbachev","year":"2001","journal-title":"Crit Rev Immunol"},{"key":"10.1067\/mai.2003.78_bib26","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1001\/archderm.136.2.272","article-title":"North American Contact Dermatitis Group patch-test results","volume":"136","author":"Marks","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1067\/mai.2003.78_bib27","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1046\/j.1365-2133.2001.04441.x","article-title":"Current concepts in contact dermatitis","volume":"145","author":"English","year":"2001","journal-title":"Br J Dermatol"},{"issue":"1 Suppl","key":"10.1067\/mai.2003.78_bib28","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1067\/mjd.2001.109815","article-title":"Cellular and immunologic mechanisms in atopic dermatitis","volume":"44","author":"Leung","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mai.2003.78_bib29","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1001\/archderm.134.7.799","article-title":"Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels","volume":"134","author":"Stevens","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1067\/mai.2003.78_bib30","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4049\/jimmunol.168.1.505","article-title":"Decreased IL-15 may contribute to elevated IgE and acute inflammation in atopic dermatitis","volume":"168","author":"Ong","year":"2002","journal-title":"J Immunol"},{"key":"10.1067\/mai.2003.78_bib31","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.med.50.1.425","article-title":"Chemokines and chemokine receptors: Biology and clinical relevance in inflammation and AIDS","volume":"50","author":"Locati","year":"1999","journal-title":"Annu Rev Med"},{"key":"10.1067\/mai.2003.78_bib32","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1046\/j.1523-1747.2000.00115.x","article-title":"A Th2 chemokine, TARC, produced by keratinocytes may recruit CLA+CCR4+ lymphocytes into lesional atopic dermatitis skin","volume":"115","author":"Vestergaard","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1067\/mai.2003.78_bib33","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1067\/mai.2001.113237","article-title":"Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity","volume":"107","author":"Kakinuma","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1067\/mai.2003.78_bib34","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.4049\/jimmunol.164.3.1612","article-title":"Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES","volume":"164","author":"Nickel","year":"2000","journal-title":"J Immunol"},{"key":"10.1067\/mai.2003.78_bib35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1034\/j.1399-3038.2000.00071.x","article-title":"Diagnosis of IgE-mediated food allergy among Swiss children with atopic dermatitis","volume":"11","author":"Eigenmann","year":"2000","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1067\/mai.2003.78_bib36","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1525-1470.1993.tb00364.x","article-title":"Eczematous skin reaction from patch testing with aeroallergens in atopic children with and without atopic dermatitis","volume":"10","author":"Wananukul","year":"1993","journal-title":"Pediatr Dermatol"},{"key":"10.1067\/mai.2003.78_bib37","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1034\/j.1398-9995.2001.00146.x","article-title":"Bacterial infections and atopic dermatitis","volume":"56","author":"Breuer","year":"2001","journal-title":"Allergy"},{"key":"10.1067\/mai.2003.78_bib38","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1067\/mai.2001.117455","article-title":"Fibronectin and fi-brinogen contribute to the enhanced binding of Staphylococcus aureus to atopic skin","volume":"108","author":"Cho","year":"2001","journal-title":"J Allergy Clin Immunol"},{"issue":"1 Suppl","key":"10.1067\/mai.2003.78_bib39","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1067\/mjd.2001.109811","article-title":"Current management and therapy of atopic dermatitis","volume":"44","author":"Tofte","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"1 Suppl","key":"10.1067\/mai.2003.78_bib40","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1067\/mjd.2001.109813","article-title":"A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients","volume":"44","author":"Paller","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mai.2003.78_bib41","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(00)05114-X","article-title":"Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: A randomised controlled trial","volume":"357","author":"Reynolds","year":"2001","journal-title":"Lancet"},{"key":"10.1067\/mai.2003.78_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.0307-6938.2001.00955.x","article-title":"A review of high-dose intravenous immunoglobulin treatment for atopic dermatitis","volume":"27","author":"Jolles","year":"2002","journal-title":"Clin Exp Dermatol"},{"key":"10.1067\/mai.2003.78_bib43","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/1523-1747.ep12297888","article-title":"Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis","volume":"107","author":"Hanifin","year":"1996","journal-title":"J Invest Dermatol"},{"key":"10.1067\/mai.2003.78_bib44","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1067\/mjd.2002.122759","article-title":"Chronic urticaria","volume":"46","author":"Grattan","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mai.2003.78_bib45","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1365-2133.1986.tb04065.x","article-title":"A serological mediator in chronic idiopathic urticaria\u2014a clinical, immunological and histological evaluation","volume":"114","author":"Grattan","year":"1986","journal-title":"Br J Dermatol"},{"key":"10.1067\/mai.2003.78_bib46","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJM199306033282204","article-title":"Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria","volume":"328","author":"Hide","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1067\/mai.2003.78_bib47","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1172\/JCI118325","article-title":"Serum IgG autoantibodies directed against the alpha chain of Fc epsilon RI: A selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients?","volume":"96","author":"Fiebiger","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1067\/mai.2003.78_bib48","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1172\/JCI511","article-title":"Anti-FcepsilonRIalpha autoantibodies in autoimmune-mediated disorders. Identification of a structure-function relationship","volume":"101","author":"Fiebiger","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1067\/mai.2003.78_bib49","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1001\/archderm.136.1.106","article-title":"End of the century overview of blisters","volume":"136","author":"Diaz","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1067\/mai.2003.78_bib50","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/35043032","article-title":"Are desmosomes more than tethers for intermediate filaments?","volume":"1","author":"Green","year":"2000","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1067\/mai.2003.78_bib51","first-page":"654","article-title":"Pemphigus","author":"Stanley","year":"1999"},{"key":"10.1067\/mai.2003.78_bib52","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jama.285.5.652","article-title":"Research advances in pemphigus","volume":"285","author":"Anhalt","year":"2001","journal-title":"JAMA"},{"key":"10.1067\/mai.2003.78_bib53","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1172\/JCI10305","article-title":"Antibodies against keratinocyte antigens other than desmogleins 1 and 2 can induce pemphigus vulgaris-like lesions","volume":"106","author":"Nguyen","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1067\/mai.2003.78_bib54","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/jama.282.6.572","article-title":"Pemphigus-diseases of antidesmosomal autoimmunity","volume":"282","author":"Udey","year":"1999","journal-title":"JAMA"},{"key":"10.1067\/mai.2003.78_bib55","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1083\/jcb.137.5.1091","article-title":"Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris","volume":"137","author":"Koch","year":"1997","journal-title":"J Cell Biol"},{"key":"10.1067\/mai.2003.78_bib56","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/1521-4141(200203)32:3<627::AID-IMMU627>3.0.CO;2-1","article-title":"Pathogenic autoantibody production requires loss of tolerance against desmoglein 3 in both T and B cells in experimental pemphigus vulgaris","volume":"32","author":"Tsundo","year":"2002","journal-title":"Eur J Immunol"},{"key":"10.1067\/mai.2003.78_bib57","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1046\/j.1365-2133.1999.02752.x","article-title":"Usefulness of enzyme-linked immunoadsorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis","volume":"140","author":"Amagai","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1067\/mai.2003.78_bib58","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/81385","article-title":"Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1","volume":"6","author":"Amagai","year":"2000","journal-title":"Nat Med"},{"key":"10.1067\/mai.2003.78_bib59","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1046\/j.1523-1747.2002.01751.x","article-title":"Staphylococcal exfoliative toxin B specifically cleaves desmoglein 1","volume":"118","author":"Amagai","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1067\/mai.2003.78_bib60","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/jmedent\/35.2.120","article-title":"Comparison of black fly species (Diptera: Simuliidae) on an Amerindian reservation with a high prevalence of fogo salvagem to neighboring disease-free sites in the State of Mato Grosso do Sol, Brazil","volume":"35","author":"Eaton","year":"1998","journal-title":"J Med Entomol"},{"key":"10.1067\/mai.2003.78_NEWBIB1","first-page":"77","article-title":"Paraneoplastic pemphigus","volume":"12","author":"Anhalt","year":"1997","journal-title":"Adv Dermatol"},{"key":"10.1067\/mai.2003.78_bib62","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1046\/j.1523-1747.1998.00279.x","article-title":"The members of the plakin family recognized by paraneoplastic pemphigus antibodies include periplakin","volume":"111","author":"Mahoney","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1067\/mai.2003.78_bib63","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1172\/JCI3647","article-title":"Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in the sera of patients with paraneoplastic pemphigus and cause acantholysis in neonatal mice","volume":"102","author":"Amagai","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1067\/mai.2003.78_bib64","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/archderm.136.5.652","article-title":"Lichenoid dermatitis in paraneoplastic pemphigus: A pathogenic trigger of epitope spreading?","volume":"136","author":"Bowen","year":"2000","journal-title":"Arch Dermatol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674902913400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674902913400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T09:23:28Z","timestamp":1553678608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674902913400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,2]]}},"alternative-id":["S0091674902913400"],"URL":"https:\/\/doi.org\/10.1067\/mai.2003.78","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2003,2]]}}}